The Adventist Health System has named Terry Shaw as the organization’s new president and chief executive officer. Shaw will immediately assume leadership responsibilities for the faith-based health care system.
The system includes 46 hospital campuses in 10 states, as well as a host of urgent care centers, home health and hospice agencies, physician practices and skilled nursing facilities.
Shaw’s career with Adventist Health System spans more than 30 years. Immediately prior to being named president/CEO, he served as executive vice president, chief financial officer and chief operations officer, where his grasp of healthcare finance, IT and overall operations enabled him to help define the organization’s vision and direction.
He began his career with AHS as a business intern in 1982. He was appointed director at Florida Hospital in 1985, assistant vice president in 1990, vice president in 1992 and senior vice president in 1996. In 2000, Shaw became senior vice president and chief financial officer for AHS, a role he held until 2010 when he gained COO responsibilities.
Shaw received bachelor’s degrees in accounting and computer science from Southern Adventist University, and a master’s degree in administration from the University of Central Florida.
He currently serves as vice chairman of the Premier board of directors and is a member of the Hospital Financial Management Association, American College of Healthcare Executives and State of Texas Board of Certified Accountants. As a silver level Leadership Society contributor to the United Way, Shaw supports and donates to the nonprofit organization, and is also active with several other professional and service organizations.
He and his wife, Paula, reside in Orlando, Florida and have two adult sons. Don Jernigan, who officially retired as Adventist Health System’s president/CEO on Dec. 8 after leading the organization for more than a decade, will transition to a faculty role at the Adventist Health System Leadership Institute.
By Jeff Lagasse
Source: Healthcare Finance
Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.
Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.
Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.